360 related articles for article (PubMed ID: 30822174)
1. The prevalence and disease burden of severe eosinophilic asthma in Japan.
Nagasaki T; Sato K; Kume N; Oguma T; Sunadome H; Ito I; Izuhara Y; Okamoto K; Kobayashi S; Ohno T; Mizukami A; Kobayashi A; Kaise T; Kuroda T; Mishima M; Matsumoto H
J Asthma; 2019 Nov; 56(11):1147-1158. PubMed ID: 30822174
[No Abstract] [Full Text] [Related]
2. Real-life retrospective observational study to determine the prevalence and economic burden of severe asthma in Spain.
Sicras-Mainar A; Capel M; Navarro-Artieda R; Nuevo J; Orellana M; Resler G
J Med Econ; 2020 May; 23(5):492-500. PubMed ID: 31958257
[No Abstract] [Full Text] [Related]
3. Severe eosinophilic asthma treated with mepolizumab stratified by baseline eosinophil thresholds: a secondary analysis of the DREAM and MENSA studies.
Ortega HG; Yancey SW; Mayer B; Gunsoy NB; Keene ON; Bleecker ER; Brightling CE; Pavord ID
Lancet Respir Med; 2016 Jul; 4(7):549-556. PubMed ID: 27177493
[TBL] [Abstract][Full Text] [Related]
4. Blood eosinophil count and prospective annual asthma disease burden: a UK cohort study.
Price DB; Rigazio A; Campbell JD; Bleecker ER; Corrigan CJ; Thomas M; Wenzel SE; Wilson AM; Small MB; Gopalan G; Ashton VL; Burden A; Hillyer EV; Kerkhof M; Pavord ID
Lancet Respir Med; 2015 Nov; 3(11):849-58. PubMed ID: 26493938
[TBL] [Abstract][Full Text] [Related]
5. The burden of adult asthma in Finland: impact of disease severity and eosinophil count on health care resource utilization.
Viinanen A; Lassenius MI; Toppila I; Karlsson A; Veijalainen L; Idänpään-Heikkilä JJ; Laitinen T
J Asthma; 2020 Oct; 57(10):1092-1102. PubMed ID: 31267775
[No Abstract] [Full Text] [Related]
6. Benralizumab efficacy by atopy status and serum immunoglobulin E for patients with severe, uncontrolled asthma.
Chipps BE; Newbold P; Hirsch I; Trudo F; Goldman M
Ann Allergy Asthma Immunol; 2018 May; 120(5):504-511.e4. PubMed ID: 29409951
[TBL] [Abstract][Full Text] [Related]
7. High blood eosinophil count is a risk factor for future asthma exacerbations in adult persistent asthma.
Zeiger RS; Schatz M; Li Q; Chen W; Khatry DB; Gossage D; Tran TN
J Allergy Clin Immunol Pract; 2014; 2(6):741-50. PubMed ID: 25439366
[TBL] [Abstract][Full Text] [Related]
8. Proportion of Severe Asthma Patients Eligible for Mepolizumab Therapy by Age and Age of Onset of Asthma.
Comberiati P; McCormack K; Malka-Rais J; Spahn JD
J Allergy Clin Immunol Pract; 2019; 7(8):2689-2696.e2. PubMed ID: 31201938
[TBL] [Abstract][Full Text] [Related]
9. Economic analysis of the phase III MENSA study evaluating mepolizumab for severe asthma with eosinophilic phenotype.
Basu A; Dalal A; Canonica GW; Forshag M; Yancey SW; Nagar S; Bell CF
Expert Rev Pharmacoecon Outcomes Res; 2017 Apr; 17(2):121-131. PubMed ID: 28277854
[TBL] [Abstract][Full Text] [Related]
10. Implication of fraction of exhaled nitric oxide and blood eosinophil count in severe asthma.
Soma T; Iemura H; Naito E; Miyauchi S; Uchida Y; Nakagome K; Nagata M
Allergol Int; 2018 Sep; 67S():S3-S11. PubMed ID: 29754974
[TBL] [Abstract][Full Text] [Related]
11. Biomarkers for severe eosinophilic asthma.
Yancey SW; Keene ON; Albers FC; Ortega H; Bates S; Bleecker ER; Pavord I
J Allergy Clin Immunol; 2017 Dec; 140(6):1509-1518. PubMed ID: 29221581
[TBL] [Abstract][Full Text] [Related]
12. Burden of asthma exacerbations and health care utilization in pediatric patients with asthma in the US and England.
Gokhale M; Hattori T; Evitt L; Lenney W; Nordstrom B; Collins J; Schultze A; Van Dyke MK
Immun Inflamm Dis; 2020 Jun; 8(2):236-245. PubMed ID: 32222038
[TBL] [Abstract][Full Text] [Related]
13. Eosinophilic and Noneosinophilic Asthma: An Expert Consensus Framework to Characterize Phenotypes in a Global Real-Life Severe Asthma Cohort.
Heaney LG; Perez de Llano L; Al-Ahmad M; Backer V; Busby J; Canonica GW; Christoff GC; Cosio BG; FitzGerald JM; Heffler E; Iwanaga T; Jackson DJ; Menzies-Gow AN; Papadopoulos NG; Papaioannou AI; Pfeffer PE; Popov TA; Porsbjerg CM; Rhee CK; Sadatsafavi M; Tohda Y; Wang E; Wechsler ME; Alacqua M; Altraja A; Bjermer L; Björnsdóttir US; Bourdin A; Brusselle GG; Buhl R; Costello RW; Hew M; Koh MS; Lehmann S; Lehtimäki L; Peters M; Taillé C; Taube C; Tran TN; Zangrilli J; Bulathsinhala L; Carter VA; Chaudhry I; Eleangovan N; Hosseini N; Kerkhof M; Murray RB; Price CA; Price DB
Chest; 2021 Sep; 160(3):814-830. PubMed ID: 33887242
[TBL] [Abstract][Full Text] [Related]
14. Disease burden and efficacy of mepolizumab in patients with severe asthma and blood eosinophil counts of ≥150-300 cells/μL.
Yancey SW; Bradford ES; Keene ON
Respir Med; 2019 May; 151():139-141. PubMed ID: 31047111
[TBL] [Abstract][Full Text] [Related]
15. Healthcare resource use and costs of severe, uncontrolled eosinophilic asthma in the UK general population.
Kerkhof M; Tran TN; Soriano JB; Golam S; Gibson D; Hillyer EV; Price DB
Thorax; 2018 Feb; 73(2):116-124. PubMed ID: 28918400
[TBL] [Abstract][Full Text] [Related]
16. Long-term safety and pharmacodynamics of mepolizumab in children with severe asthma with an eosinophilic phenotype.
Gupta A; Ikeda M; Geng B; Azmi J; Price RG; Bradford ES; Yancey SW; Steinfeld J
J Allergy Clin Immunol; 2019 Nov; 144(5):1336-1342.e7. PubMed ID: 31425781
[TBL] [Abstract][Full Text] [Related]
17. Epidemiological, clinical and economic burden of severe eosinophilic asthma in Taiwan: Results from a large tertiary care hospital.
Shantakumar S; Ho YF; Tuan LW; Lin TM; Hershko AY; Chen YH
Asian Pac J Allergy Immunol; 2023 Dec; 41(4):325-335. PubMed ID: 33274956
[TBL] [Abstract][Full Text] [Related]
18. Blood eosinophil count is a useful biomarker to identify patients with severe eosinophilic asthma.
Katz LE; Gleich GJ; Hartley BF; Yancey SW; Ortega HG
Ann Am Thorac Soc; 2014 May; 11(4):531-6. PubMed ID: 24606022
[TBL] [Abstract][Full Text] [Related]
19. Efficacy of mepolizumab for patients with severe asthma and eosinophilic chronic rhinosinusitis.
Numata T; Nakayama K; Utsumi H; Kobayashi K; Yanagisawa H; Hashimoto M; Minagawa S; Ishikawa T; Hara H; Araya J; Kuwano K
BMC Pulm Med; 2019 Oct; 19(1):176. PubMed ID: 31606052
[TBL] [Abstract][Full Text] [Related]
20. Long-term effectiveness of benralizumab in severe eosinophilic asthma patients treated for 96-weeks: data from the ANANKE study.
Vultaggio A; Aliani M; Altieri E; Bracciale P; Brussino L; Caiaffa MF; Cameli P; Canonica GW; Caruso C; Centanni S; D'Amato M; De Michele F; Del Giacco S; Di Marco F; Menzella F; Pelaia G; Rogliani P; Romagnoli M; Schino P; Senna G; Benci M; Boarino S; Schroeder JW
Respir Res; 2023 May; 24(1):135. PubMed ID: 37210543
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
